Payment overview · 2025
General Payments
$1,338.83
39 reported records · 12 companies
Healthcare provider profile · identity verified
Amanda Lee West, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · HILLIARD, FL · NPI 1063706026
Verified facts
What the public records show
CMS Open Payments records show Amanda Lee West, APRN received $1,338.83 in general payments during 2025 across 39 reported records.
Corcept Therapeutics accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $384.70 | 28.7% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $258.36 | 19.3% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $167.41 | 12.5% | 8 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $152.12 | 11.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $131.73 | 9.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $74.94 | 5.6% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $47.28 | 3.5% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.09 | 2.5% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $30.98 | 2.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.65 | 1.8% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.72 | 1.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.85 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,338.83 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $384.70 | 9 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $258.36 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $167.41 | 8 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $152.12 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $131.73 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $74.94 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $47.28 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $33.09 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $30.98 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $29.71 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $24.65 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.72 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
62 | 17 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 306 | 92 |
| Amlodipine Besylate | Amlodipine Besylate | 225 | 72 |
| Omeprazole | Omeprazole | 172 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 156 | 46 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 140 | 50 |
| Prednisone | Prednisone | 135 | 80 |
| Gabapentin | Gabapentin | 129 | 46 |
| Metformin Hcl | Metformin Hcl | 127 | 39 |
| Losartan Potassium | Losartan Potassium | 119 | 36 |
| Lisinopril | Lisinopril | 110 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 107 | 37 |
| Montelukast Sodium | Montelukast Sodium | 100 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 88 | 28 |
| Sertraline Hcl | Sertraline Hcl | 66 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 64 | 21 |
| Eliquis | Apixaban | 62 | 17 |
| Potassium Chloride | Potassium Chloride | 62 | 23 |
| Carvedilol | Carvedilol | 60 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 58 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 56 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 41 |
| Furosemide | Furosemide | 53 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 17 |
| Mounjaro | Tirzepatide | 52 | suppressed |
| Pregabalin | Pregabalin | 50 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 50 | 19 |
| Jardiance | Empagliflozin | 49 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 33 |
| Ezetimibe | Ezetimibe | 48 | 18 |
| Spironolactone | Spironolactone | 47 | 12 |
| Alprazolam | Alprazolam | 46 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 46 | 13 |
| Ozempic | Semaglutide | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | 13 |
| Fluticasone Propionate | Fluticasone Propionate | 45 | 13 |
| Clopidogrel | Clopidogrel Bisulfate | 41 | 16 |
| Lorazepam | Lorazepam | 39 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 39 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Ibuprofen | Ibuprofen | 38 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 38 | 14 |
| Ondansetron Odt | Ondansetron | 36 | 16 |
| Allopurinol | Allopurinol | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 34 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 34 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 33 | 18 |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Nystatin | Nystatin | 31 | 11 |
| Simvastatin | Simvastatin | 31 | 11 |
| Temazepam | Temazepam | 31 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Valsartan | Valsartan | 30 | suppressed |
| Entresto | Sacubitril/Valsartan | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 22 |
| Glipizide | Glipizide | 26 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 26 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Meloxicam | Meloxicam | 24 | suppressed |
| Azithromycin | Azithromycin | 23 | 22 |
| Clonazepam | Clonazepam | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Famotidine | Famotidine | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 12 |
| Metformin Hcl Er | Metformin Hcl | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Diazepam | Diazepam | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Donepezil Hcl | Donepezil Hcl | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,338.83 · 39 records | Corcept Therapeutics | AIRSUPRA, Auvelity, CAMZYOS, CAPLYTA, Cologuard Collection Kit, FARXIGA, FREESTYLE LIBRE 3, Kerendia, Korlym, Qelbree, TZIELD, VRAYLAR, Veozah | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error